Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors

Core Insights - Samsung Bioepis and Phrontline Biopharma have entered into a global collaboration agreement to develop, manufacture, and commercialize two Antibody-Drug Conjugate (ADC) assets [1] - The ADC assets include TJ108, which is a bispecific and dual-payload ADC, and another unnamed asset [1] - Samsung Bioepis will receive an exclusive license from Phrontline for one of the ADC assets [1]